2180 days ago
We still have some warrants in Amryt (AMYT) and I know this is a big year both in terms of clinical trials and also sales ramp up but I admit that I am a bit off the pace on exactly what is going on. So over to someone who is bang up to speed.
2419 days ago
Amryt Pharma (AMYT) has announced results for the six months ended 30 June 2017. There were no great shocks the buy case is compelling and low risk - my target, for shares I admit to owning, is very conservative. Others are twice as ambitious or more!
2529 days ago
Take a look! European investors are clearly failing to grasp the very significant financial and commercial benefits available for Orphan or Rare Disease drug developers. So much so in fact, that sector-focussed Amryt Pharma (AMYT) finds no quoted peers in London, yet a good basket of NASDAQ-listed comparables are seen to command a significant premium despite mostly being pre-revenue and somewhat earlier in their development. Such anomalies can and, of course, do rapidly correct.
2580 days ago
Shares in Amryt Pharma (AMYT) are starting to move the right way and ever faster;as clear progress is made with its portfolio. On Tuesday we had the, not unexpected, news that it has started the phase 3 ( that is to say final human) trials of AP101, its lead drug candidate, a potential treatment for Epidermolysis Bullosa (EB). EB is a rare, genetic skin disorder, which causes exceptionally fragile skin
2672 days ago
Boy did Amryt bore its loyal shareholders, including us, to tears for most of 2016. Owning this stock, formerly a failed oil explorer Fastnet, was like watching paint dry. Amid a totally understandable ennui the shares drifted back to lows of just under 14p which - as we had tipped the shares at 18.4p and bought ourselves at higher levels - was a bit of a pain. But then in November it roared into life and the shares are now 18.5p-20.5p and are my second buy tip of the year at up to 22p.
2699 days ago
I am a loyal shareholder and think that shares in Amryt (AMYT) are cheap and a deal today really does look like very good news indeed. But the buy note from broker Stifel has me a bit confused. Let me explain.
2704 days ago
Amryt Pharma (AMYT) has announced that it has secured a €20m debt facility from the European Investment Bank on, what broker Stifel says, are very attractive commercial terms. Stifel says that the facility will not only extend the company's funding until well into 2019, but also provide funding for development of acromegaly product AP102 and potential launch funding for Episalvan in partial thickness wounds. Stifel concludes that the shares are a buy at 14p with a price target of 49p. Yes indeed. Since we own the shares I thought we'd share the note with you.
